文献速递脊柱关节炎

银屑病关节炎患者启用首个TNF抑制剂后DAPSA28缓解的预测因素:来自13个欧洲登记处的结

Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

在未使用过生物制剂的银屑病关节炎患者中,13个欧洲登记处汇总队列(n=13369)显示6个月DAPSA28缓解率25%、中度应答率34%、12个月药物留存率63%。年龄、病程、性别、CRP和疲劳评分是缓解、应答和留存的共同基线预测因素。

要点

  • 汇总队列6个月DAPSA28缓解率25%,中度应答率34%,12个月药物留存率63%。
  • 男性较女性缓解OR 1.85(95%CI 1.54-2.23),CRP>10 vs ≤10 mg/l的OR 1.52(95%CI 1.22-1.89)。
  • 病程≥10年 vs <2年缓解OR 1.66(95%CI 1.26-2.20),年龄每增1岁OR 0.97(95%CI 0.96-0.98)。

核心结论

  • 基线可识别DAPSA28缓解、中度应答和12个月药物留存的预测因素,其中5个为三项结局的共同预测因素。
  • 作者认为汇总队列中出现的预测因素可能可从国家层面推广至疾病层面。

研究设计与样本

  • 基于13个欧洲登记处的观察性队列研究,纳入未使用过生物制剂、启用首个TNF抑制剂的银屑病关节炎患者。
  • 对每个登记处及汇总数据分别用多重插补后的逻辑回归分析三项结局,汇总队列n=13369。

主要发现

  • 汇总队列中6个月缓解、中度应答和12个月药物留存的比例分别为25%、34%和63%(有可用数据者分别为n=6954、n=5275和n=13369)。
  • DAPSA28缓解的OR(95%CI):年龄每增1岁0.97(0.96-0.98);病程以<2年为参照,2-3年1.20(0.89-1.60)、4-9年1.42(1.09-1.84)、≥10年1.66(1.26-2.20)。
  • DAPSA28缓解的OR(95%CI):男性 vs 女性1.85(1.54-2.23);CRP>10 vs ≤10 mg/l为1.52(1.22-1.89);患者疲劳评分每增1 mm为0.99(0.98-0.99)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In bio-naïve patients with PsA initiating a TNF inhibitor (TNFi), we aimed to identify baseline predictors of Disease Activity index for PsA in 28 joints (DAPSA28) remission (primary objective) and DAPSA28 moderate response at 6 months, as well as drug retention at 12 months across 13 European registries. METHODS: Baseline demographic and clinical characteristics were retrieved and the three outcomes investigated per registry and in pooled data, using logistic regression analyses on multiply imputed data. In the pooled cohort, selected predictors that were either consistently positive or negative across all three outcomes were defined as common predictors. RESULTS: In the pooled cohort (n = 13 369), 6-month proportions of remission, moderate response and 12-month drug retention were 25%, 34% and 63% in patients with available data (n = 6954, n = 5275 and n = 13 369, respectively). Five common baseline predictors of remission, moderate response and 12-month drug retention were identified across all three outcomes. The odds ratios (95% CIs) for DAPSA28 remission were: age, per year: 0.97 (0.96-0.98); disease duration, years (<2 years as reference): 2-3 years: 1.20 (0.89-1.60), 4-9 years: 1.42 (1.09-1.84), ≥10 years: 1.66 (1.26-2.20); men vs women: 1.85 (1.54-2.23); CRP of >10 vs ≤10 mg/l: 1.52 (1.22-1.89) and 1 mm increase in patient fatigue score: 0.99 (0.98-0.99). CONCLUSION: Baseline predictors of remission, response and adherence to TNFi therapy were identified, of which five were common for all three outcomes, indicating that the predictors emerging from our pooled cohort may be considered generalizable from country level to disease level.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Linde L, Ørnbjerg LM, Georgiadis S, et al. Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries. Rheumatology (Oxford). 2024. PMID: 37314967. doi:10.1093/rheumatology/kead284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。